LIBERTY® Endovascular Robotic System Debuts in Michigan Through Leading Health System
Microbot Medical Inc. (Nasdaq: MBOT), developer and distributor of the innovative LIBERTY® Endovascular Robotic System, announced that one of the largest healthcare systems in Michigan is the first health network in Michigan and across the greater Midwest U.S. to adopt the LIBERTY System. This adoption follows the Company’s recent announcement of its first healthcare system customer in North Carolina further expanding LIBERTY’s presence across multiple strategic U.S regions and reinforcing growing interest among health systems.
The Company believes the ongoing progress across new and existing sales territories reflects growing demand for advanced robotic solutions in peripheral endovascular procedures, as well as increasing readiness among major health systems to integrate robotics into routine vascular care. This trend continues to validate Microbot Medical’s recent successful transition to full market release in the U.S.
The U.S. market for peripheral endovascular procedures encompasses approximately 2.5 million procedures annually, representing a significant and expanding clinical and commercial opportunity.
“We are excited to see the continued expansion of the LIBERTY System into new healthcare systems across the country,” commented Harel Gadot Chairman, President & CEO. “We believe the addition of another healthcare system custome following our recent expansion into North Carolina reflects the growing recognition that robotics can be delivered in a way that is practical, accessible and aligned with the needs of today’s healthcare environment. We are seeing increasing interest from physicians and hospital leaders who recognize LIBERTY’s potential to enhance procedural workflows while supporting physician well-being. We believe this positions us well for continued growth, increased utilization across our commercial accounts, and to further market penetration.”
LIBERTY is the only FDA-cleared, single-use, remotely operated robotic system for peripheral endovascular procedures, and it is designed for precise vascular navigation while aiming to reduce radiation exposure and physical strain. Recently, the LIBERTY System received regulatory approval from the Israeli Ministry of Health’s AMAR Division, the authority responsible for medical device regulation in Israel, allowing the Company to market and sell the LIBERTY System in Israel.
